Literature DB >> 16779704

Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

Chun Chu1, Yun Zhang, Ruben J Boado, William M Pardridge.   

Abstract

PURPOSE: Nonviral gene transfer to the brain of adult Rhesus monkeys is possible with a single intravenous administration of plasmid DNA that is encapsulated in the interior of pegylated immunoliposomes, which are targeted across membrane barriers in vivo with a monoclonal antibody to the human insulin receptor.
METHODS: The present studies measure the rate of decay of luciferase gene expression in the Rhesus monkey with luciferase enzyme assays, Southern blotting, and real-time polymerase chain reaction.
RESULTS: Luciferase enzyme activity in frontal cortex, cerebellum, and liver decays with a t(1/2) of 2.1 +/- 0.1, 2.6 +/- 0.2, and 1.7 +/- 0.01 days, respectively. Luciferase plasmid in brain and liver was detectable by Southern blotting at 2 days, but not at 7 or 14 days. The concentration of luciferase plasmid DNA in brain and liver was measured by real-time polymerase chain reaction, and decayed with t(1/2) of 1.3 +/- 0.3 and 2.7 +/- 0.5 days, respectively.
CONCLUSIONS: The maximal concentration of luciferase plasmid DNA in Rhesus monkey brain was 3-4 molecules/cell following an i.v. administration of 12 microg/kg pegylated immunoliposome encapsulated plasmid DNA. These results demonstrate that the rate of loss of exogenous gene expression in the primate in vivo correlates with the rate of DNA degradation of the exogenous plasmid DNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779704     DOI: 10.1007/s11095-006-0274-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer.

Authors:  D Lechardeur; K J Sohn; M Haardt; P B Joshi; M Monck; R W Graham; B Beatty; J Squire; H O'Brodovich; G L Lukacs
Journal:  Gene Ther       Date:  1999-04       Impact factor: 5.250

2.  An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo.

Authors:  Bok Hee C Jenke; Christian P Fetzer; Isa M Stehle; Franziska Jönsson; Frank O Fackelmayer; Harald Conradt; Jürgen Bode; Hans J Lipps
Journal:  EMBO Rep       Date:  2002-03-15       Impact factor: 8.807

3.  Gene targeting in vivo with pegylated immunoliposomes.

Authors:  William M Pardridge
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

4.  Ten nucleotide cis element in the 3'-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization.

Authors:  R J Boado; W M Pardridge
Journal:  Brain Res Mol Brain Res       Date:  1998-08-15

5.  High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.

Authors:  N S Yew; M Przybylska; R J Ziegler; D Liu; S H Cheng
Journal:  Mol Ther       Date:  2001-07       Impact factor: 11.454

6.  Brain-specific expression of an exogenous gene after i.v. administration.

Authors:  N Shi; Y Zhang; C Zhu; R J Boado; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

7.  DNAzol: a reagent for the rapid isolation of genomic DNA.

Authors:  P Chomczynski; K Mackey; R Drews; W Wilfinger
Journal:  Biotechniques       Date:  1997-03       Impact factor: 1.993

8.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

Authors:  Yun Zhang; Frederic Calon; Chunni Zhu; Ruben J Boado; William M Pardridge
Journal:  Hum Gene Ther       Date:  2003-01-01       Impact factor: 5.695

9.  Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate.

Authors:  W M Pardridge; Y S Kang; J L Buciak; J Yang
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo.

Authors:  Z Y Chen; C Y He; L Meuse; M A Kay
Journal:  Gene Ther       Date:  2004-05       Impact factor: 5.250

View more
  8 in total

Review 1.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 2.  Nanoparticle transport across the blood brain barrier.

Authors:  Andreas M Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Tissue Barriers       Date:  2016-02-25

Review 3.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 4.  Blood-brain barrier transport of non-viral gene and RNAi therapeutics.

Authors:  Ruben J Boado
Journal:  Pharm Res       Date:  2007-06-08       Impact factor: 4.200

5.  Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer.

Authors:  Yun Zhang; Yuntao Wang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2007-06-30       Impact factor: 4.200

Review 6.  Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Authors:  William M Pardridge
Journal:  Front Med Technol       Date:  2020-11-16

7.  The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier.

Authors:  Ruben J Boado; William M Pardridge
Journal:  J Drug Deliv       Date:  2011-11-16

8.  Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes.

Authors:  Dahai Jiang; Hungyen Lee; William M Pardridge
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.